Aditya Bardia, MD, MPH

Articles

The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings

July 25th 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials

July 25th 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Dr Bardia on Results of the NATALEE Trial in HR+/HER2– Early Breast Cancer

June 7th 2023

Aditya Bardia, MD, MPH, discusses the investigation of ribociclib and endocrine therapy vs endocrine therapy alone as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer, highlighting primary results from the phase 3 NATALEE trial.

Evolution in the Field of HR+ Breast Cancer Management

March 16th 2023

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Other Treatment Modalities for HR+ Metastatic Breast Cancer

March 9th 2023

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners

March 9th 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Advice for Community Physicians on Managing HER2+ Breast Cancer

March 7th 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer

March 2nd 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer

March 2nd 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer

February 28th 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Optimizing Real-World Management of HER2-Low Breast Cancer

February 28th 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

February 23rd 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.